文献速递银屑病与炎症性皮肤病

Ixekizumab改善中重度生殖器银屑病继发皮损、疼痛与性健康

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-02-05

本分析基于IXORA-Q IIIb期随机双盲安慰剂对照研究(NCT02718898)的149例中重度生殖器银屑病成人患者,评估生殖器糜烂、裂隙和/或溃疡对疼痛与性活动的影响及ixekizumab至第12周的疗效。结果显示,ixekizumab组这些体征的完全消退率第1周为62%(安慰剂25%)、第12周为83%(安慰剂21%),并显著改善疼痛、瘙痒、疾病严重度和性健康。

要点

  • 基线38%患者存在生殖器糜烂、裂隙和/或溃疡,与更高sPGA-G和GPSS疼痛评分相关。
  • ixekizumab组体征完全消退率第1周62%、第12周83%,均高于安慰剂。
  • 无论基线有无糜烂、裂隙和/或溃疡,ixekizumab均显著改善疼痛、瘙痒、严重度与性健康。

核心结论

  • Ixekizumab可快速、持续消退生殖器银屑病的糜烂、裂隙和/或溃疡,并显著改善生殖器银屑病严重度、生殖器疼痛与性健康。

研究设计与样本

  • IXORA-Q(NCT02718898)为IIIb期多中心、随机、双盲、安慰剂对照研究的事后亚组分析。
  • 共纳入149例中重度生殖器银屑病成人患者,ixekizumab 80 mg每2周皮下注射组n=75,安慰剂组n=74。
  • 评估工具包括sPGA-G、GPSS和GenPs-SFQ。

主要发现

  • 基线时38%(n=57)患者存在生殖器糜烂、裂隙和/或溃疡,与全身BSA受累(<10%或≥10%)无关。
  • 这些体征与更高的sPGA-G疾病严重度评分和GPSS疼痛评分相关,但与GenPs-SFQ性健康无关。
  • ixekizumab组体征完全消退率第1周62%(安慰剂25%)、第12周83%(安慰剂21%)。
  • ixekizumab组12周内疼痛、瘙痒、疾病严重度和性健康较安慰剂显著改善,且不受基线有无糜烂、裂隙和/或溃疡影响。

临床怎么用

  • 对中重度生殖器银屑病伴糜烂、裂隙和/或溃疡者,ixekizumab可考虑用于快速改善体征、疼痛与性健康。
  • 评估生殖器银屑病时应关注糜烂、裂隙和/或溃疡等继发体征及其对疼痛和性生活的影响。

局限性

  • 本研究为事后亚组分析,证据级别低于预设主要分析。
  • 样本量较小(共149例),亚组比较需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epithelial surface disruption in genital psoriatic lesions may manifest as erosions, fissures and/or ulcers, causing pain and significantly impacting a patient's sexual health. OBJECTIVE: To evaluate the impact of erosions, fissures and/or ulcers in genital psoriatic lesions on pain and sexual activity in patients with moderate-to-severe genital psoriasis (GenPs) and treatment responses to ixekizumab vs. placebo until Week 12. METHODS: This post hoc subgroup analysis of patients presenting with and without erosions, fissures and/or ulcers in genital lesions from a phase IIIb multicentre, randomized, double-blind, placebo-controlled study (IXORA-Q; NCT02718898) in 149 adults with moderate-to-severe GenPs treated with subcutaneous ixekizumab (80 mg every 2 weeks; n = 75) or placebo (n = 74) evaluated outcomes for clinician-rated GenPs severity (static Physician's Global Assessment of Genitalia; sPGA-G) and patient-reported genital pain and itch (Genital Psoriasis Symptoms Scale; GPSS) and sexual health (Genital Psoriasis Sexual Frequency Questionnaire; GenPs-SFQ). RESULTS: At baseline, 38% (n = 57) of patients presented with genital erosions, fissures and/or ulcers independent of overall body surface area involvement (<10% or ≥10%). These signs were associated with higher scores for disease severity (sPGA-G) and pain (GPSS) but not sexual health (GenPs-SFQ). Complete resolution of these signs was observed in 62% of ixekizumab-treated patients (25% for placebo) at Week 1 and 83% (21% for placebo) at Week 12. Patients treated with ixekizumab reported significant improvements in pain, itch, disease severity and sexual health over 12 weeks compared to placebo and irrespective of the presence/absence of genital erosions, fissures and/or ulcers at baseline. CONCLUSION: Ixekizumab led to rapid and sustained resolution of erosions, fissures and/or ulcers and significant improvements in GenPs severity, genital pain and sexual health. Ixekizumab may help to improve the well-being of patients with GenPs.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Merola JF, Ghislain PD, Dauendorffer JN, et al. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. J Eur Acad Dermatol Venereol. 2020. PMID: 31919919. doi:10.1111/jdv.16181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。